The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
 
Daniel Olson
Consulting or Advisory Role - Gerson Lehrman Group; Iovance Biotherapeutics; MJH Life Sciences; Novartis
 
Young Hong
Consulting or Advisory Role - Castle Biosciences; Iovance Biotherapeutics
 
Sajeve Samuel Thomas
Speakers' Bureau - Amgen; Bms; Genentech; ipsen; Merck; Natera; Novartis; Pfizer
 
Juan Martin-Liberal
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
 
Friedrich Graf Finckenstein
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Renee Xiao Wu
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Giri Sulur
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Wen Shi
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; GlaxoSmithKline; immatics; Pierre Fabre; Roche/Genentech